Fatal Relapse of Myelodysplastic Syndrome in a Patient with HIV/Hepatitis C Coinfection Treated with Simeprevir/Sofosbuvir

Fatal Relapse of Myelodysplastic Syndrome in a Patient with HIV/Hepatitis C Coinfection Treated with Simeprevir/Sofosbuvir

Registrational studies and observational cohorts clearly suggest sustained virologic response (SVR) rates in HIV-/hepatitis C–coinfected patients are similar to monoinfected patients when utilizing interferon-free regimens, and this can be accomplished with agents that are well tolerated with minima...

Full description

Bibliographic Details
Main Authors:	Efemena Michael Diejomaoh MD, Joseph Clayton Gathe MD, FACP, FIDSA, Carl Craig Mayberry PA-C, John Benjamin Clemmons MD, Bernie Miguel MD, Alan Glombicki MD, Benjamin Daquioag MD
Format:	Article
Language:	English
Published:	SAGE Publishing 2017-03-01
Series:	Journal of the International Association of Providers of AIDS Care
Online Access:	https://doi.org/10.1177/2325957416686837

Similar Items

Fecal Transplantation for —“All Stool May Not Be Created Equal”
by: Joseph C. Gathe MD, FACP, FIDSA, et al.
Published: (2016-03-01)

Multicenter Experience using Ledipasvir/Sofosbuvir ± RBV to Treat HCV GT 1 Relapsers after Simeprevir and Sofosbuvir Treatment
by: Bashar Aqel, et al.
Published: (2018-09-01)

Successful Treatment of Hepatitis C with Simeprevir, Sofosbuvir, and Ribavirin in an HIV Coinfected Liver Transplant Patient with Advanced Chronic Kidney Disease
by: Anna Maruyama, et al.
Published: (2016-01-01)

Sofosbuvir and Simeprevir for the Treatment of Recurrent Hepatitis C with Fibrosing Cholestatic Hepatitis after Liver Transplantation
by: D Issa, et al.
Published: (2016-01-01)

Safety and efficacy of combination therapy (Simeprevir/Sofosbuvir) in the treatment of chronic HCV genotype IV patients
by: Engy A. Wahsh, et al.
Published: (2018-03-01)

Benefit–risk assessment of new and emerging treatments for hepatitis C: focus on simeprevir and sofosbuvir
by: Gaetano JN
Published: (2014-03-01)

Treatment of Recurrent Hepatitis C Genotype-4 Post- Liver Transplantation with Sofosbuvir plus Simeprevir
by: Mustafa Ascha, et al.
Published: (2015-04-01)

New-Onset Diabetes Mellitus With Exposure to Ledipasvir and Sofosbuvir
by: Resmi Premji MD, et al.
Published: (2015-12-01)

The impact of ribavirin on real-world adherence rates in hepatitis C patients treated with sofosbuvir plus simeprevir
by: Walker DR, et al.
Published: (2015-12-01)

A Case Series of Patients Coinfected With Influenza and COVID-19
by: Venu Madhav Konala MD, FACP, CACP, et al.
Published: (2020-06-01)

Response to Letter Regarding “A Case Series of Patients Coinfected With Influenza and COVID-19”
by: Srikanth Naramala MD, FACR, CCD, et al.
Published: (2020-10-01)

HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir
by: Harel Dahari, et al.
Published: (2016-05-01)

Treatment with ledipasvir-sofosbuvir for hepatitis C resulting in improvement of lichen planus
by: Umer Ansari, BS, et al.
Published: (2017-01-01)

Epstein-Barr Virus Coinfection in COVID-19
by: Asim Nadeem MD, et al.
Published: (2021-08-01)

Neutrophilic Dermatosis in Myelodysplastic Syndrome and Chronic Active Hepatitis C
by: Rupam Sharma MD, et al.
Published: (2021-07-01)

Simeprevir and Sofosbuvir Combination Treatment in a Patient with HCV Cirrhosis and HbS Beta 0-Thalassemia: Efficacy and Safety despite Baseline Hyperbilirubinemia
by: Nikolaos Papadopoulos, et al.
Published: (2016-01-01)

Successful Treatment Using Simeprevir, Sofosbuvir and Rituximab of a Severe Form of Hepatitis C Virus-related Mixed Cryoglobulinemia with Cardiac Involvement
by: Rafael Mahieu, et al.
Published: (2015-11-01)

Curing Chronic Hepatitis C: A Cost Comparison of the Combination Simeprevir Plus Sofosbuvir vs. Protease-Inhibitor-Based Triple Therapy
by: Jacob A. Langness, et al.
Published: (2017-05-01)

Myelodysplastic Syndrome Presenting as Amegakaryocytic Thrombocytopenia in a Collodion Baby
by: Mohammed Al Pakra MD, et al.
Published: (2015-09-01)

From Famine to a Feast: Little Endogenous Thyroxine to Overproduction
by: Amos Lal, MD, et al.
Published: (2018-09-01)

Validated Reversed-Phase Liquid Chromatographic Method with Gradient Elution for Simultaneous Determination of the Antiviral Agents: Sofosbuvir, Ledipasvir, Daclatasvir, and Simeprevir in Their Dosage Forms
by: Essam Ezzeldin, et al.
Published: (2020-10-01)

Sofosbuvir in Combination with Simeprevir +/- Ribavirin in Genotype 4 Hepatitis C Patients with Advanced Fibrosis or Cirrhosis: A Real-World Experience from Belgium.
by: Delphine Degré, et al.
Published: (2017-01-01)

Can Coinfection With Influenza Worsen COVID-19 Outcomes?
by: Kulachanya Suwanwongse MD, MSc, et al.
Published: (2020-08-01)

A Unique Case of Spontaneous Pneumomediastinum in a Patient With COVID-19 and Influenza Coinfection
by: Sathishkumar Ramalingam MD, et al.
Published: (2021-05-01)

Letter to the Editor Response on: Prosthetic Breast Reconstruction and Red Breast Syndrome
by: Matthew J. Kuehnert, MD, FACP, FIDSA, et al.
Published: (2019-11-01)

Frequent Coinfection with Hepatitis among HIV-Positive Patients in Urumqi, China
by: Rena Maimaiti MD, et al.
Published: (2013-02-01)

Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort
by: Anne Laurain, et al.
Published: (2019-04-01)

Stress-Induced Cardiomyopathy Precipitated by COVID-19 and Influenza A Coinfection
by: Charlie Joseph Sang, III, MD, et al.
Published: (2020-07-01)

Relapsed Acinic Cell Carcinoma of the Parotid Gland With Diffuse Distant Metastasis
by: Yousef Khelfa MD, FACP, et al.
Published: (2016-10-01)

Simeprevir, daclatasvir, and sofosbuvir for hepatitis C virus‐infected patients: Long‐term follow‐up results from the open‐label, Phase II IMPACT study
by: Eric Lawitz, et al.
Published: (2020-06-01)

Risk of Liver Fibrosis in Hepatitis B Virus and HIV Coinfected Youths Receiving Tenofovir-Containing Antiretroviral Regimen
by: Linda Aurpibul MD, et al.
Published: (2019-01-01)

Eight Weeks of Ledipasvir/Sofosbuvir in Kidney Transplant Recipients With Hepatitis C Genotype 1 Infection
by: Jennifer S. Husson, MD, MPH, et al.
Published: (2017-12-01)

A Case of Primary HIV Type 1 and Cytomegalovirus Coinfection Presenting with Widespread Clinical Disease
by: Joseph Y. Kim MD, et al.
Published: (2014-05-01)

Strategies for Reducing Fatal Complications in Liposuction
by: Lázaro Cárdenas-Camarena, MD, et al.
Published: (2017-10-01)

Effect of Health Insurance on Hepatitis C Sustained Virologic Response Rates to Sofosbuvir-Based Treatment Regimens in a South Florida Community Hospital
by: Paula Eckardt MD, FACP, AAHIVS, et al.
Published: (2019-03-01)

An Acute Pulmonary Coccidioidomycosis Coinfection in a Patient Presenting With Multifocal Pneumonia With COVID-19
by: Cameron Casey Chang MD, et al.
Published: (2020-11-01)

Long-Term Liver Diseases after Initiation of Antiretroviral Therapy in HIV-Infected Patients with and without HBV or HCV Coinfection
by: Sithakom Phusanti MD, et al.
Published: (2017-03-01)

Ledipasvir plus sofosbuvir in pregnant women with hepatitis C virus infection: a phase 1 pharmacokinetic study
by: Catherine A Chappell, MD, et al.
Published: (2020-09-01)

Fatal pulmonary fibrosis complicating COVID-19 infection in preexistent emphysema
by: Massimiliano Mazzolini, MD, et al.
Published: (2021-02-01)

Fatal vascular complication due to metallosis
by: Miguel García-Gimeno, MD, PhD, et al.
Published: (2021-06-01)